Novel Bidentate Amine Ligand and the Interplay between Pd(II) and Pt(II) Coordination and Biological Activity

• Main Author: Oliveira, Laiane S.
• Publication Date: 2024
• Other Authors: Rosa, Letícia B., Affonso, Daniele D., Santos, Igor A., Da Silva, Jennyfer C., Rodrigues, Gustavo C., Harris, Mark, Jardim, Ana Carolina G. [UNESP], Nakahata, Douglas H., Sabino, José R., de Carvalho, João E., Miguel, Danilo C., Ruiz, Ana Lucia T. G., Abbehausen, Camilla
• Format: Article
• Language: eng
• Source: Repositório Institucional da UNESP
• Download full: http://dx.doi.org/10.1002/cbic.202300696; https://hdl.handle.net/11449/301484
• topic: antioxidant; cancer; Palladium; Platinum; SARS-CoV-2

Pt(II) and Pd(II) coordinating N-donor ligands have been extensively studied as anticancer agents after the success of cisplatin. In this work, a novel bidentate N-donor ligand, the N-[[4-(phenylmethoxy)phenyl]methyl]-2-pyridinemethanamine, was designed to explore the antiparasitic, antiviral and antitumor activity of its Pt(II) and Pd(II) complexes. Chemical and spectroscopic characterization confirm the formation of [MLCl2] complexes, where M=Pt(II) and Pd(II). Single crystal X-ray diffraction confirmed a square-planar geometry for the Pd(II) complex. Spectroscopic characterization of the Pt(II) complex suggests a similar structure. 1H NMR, 195Pt NMR and HR-ESI-MS(+) analysis of DMSO solution of complexes indicated that both compounds exchange the chloride trans to the pyridine for a solvent molecule with different reaction rates. The ligand and the two complexes were tested for in vitro antitumoral, antileishmanial, and antiviral activity. The Pt(II) complex resulted in a GI50 of 10.5 μM against the NCI/ADR-RES (multidrug-resistant ovarian carcinoma) cell line. The ligand and the Pd(II) complex showed good anti-SARS-CoV-2 activity with around 65 % reduction in viral replication at a concentration of 50 μM.